Treatment of macrophage mediated disease

Details Treatment of macrophage mediated disease Treatment of macrophage mediated disease

2002-05-02

2010-06-22

Belyavskyi, Michail A (Department: 1644)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

C424S185100, C424S193100

Reexamination Certificate

active

07740854

ABSTRACT:
The invention relates to a method of treating or monitoring/diagnosing a disease state mediated by activated macrophages. The method comprises the step of administering to a patient suffering from a macrophage mediated disease state an effective amount of a composition comprising a conjugate or complex of the general formulain-line-formulae description="In-line Formulae" end="lead"?Ab-Xin-line-formulae description="In-line Formulae" end="tail"?where the group Abcomprises a ligand capable of binding to activated macrophages, and when the conjugate is being used for treatment of the disease state, the group X comprises an immunogen, a cytotoxin, or a compound capable of altering macrophage function, and when the conjugate is being used for monitoring/diagnosing the disease state, X comprises an imaging agent. The method is useful for treating a patient suffering from a disease selected from the group consisting of rheumatoid arthritis, ulcerative colitis, Crohn's disease, inflammation, infections, osteomyelitis, atherosclerosis, organ transplant rejection, pulmonary fibrosis, sarcoidosis, and systemic sclerosis.

REFERENCES:
patent: 2816110 (1957-12-01), Sletzinger et al.
patent: 4713249 (1987-12-01), Schroder
patent: 5057540 (1991-10-01), Kensil et al.
patent: 5094848 (1992-03-01), Brixner
patent: 5108921 (1992-04-01), Low et al.
patent: 5140104 (1992-08-01), Coughlin et al.
patent: 5266333 (1993-11-01), Cady et al.
patent: 5273965 (1993-12-01), Kensil et al.
patent: 5336506 (1994-08-01), Josephson et al.
patent: 5373093 (1994-12-01), Vallarino et al.
patent: 5399338 (1995-03-01), Born et al.
patent: 5416016 (1995-05-01), Low et al.
patent: 5417982 (1995-05-01), Modi
patent: 5443829 (1995-08-01), Kensil et al.
patent: 5508310 (1996-04-01), Rhodes
patent: 5547668 (1996-08-01), Kranz et al.
patent: 5552545 (1996-09-01), Pearce et al.
patent: 5583112 (1996-12-01), Kensil et al.
patent: 5635382 (1997-06-01), Low et al.
patent: 5650398 (1997-07-01), Kensil et al.
patent: 5688488 (1997-11-01), Low et al.
patent: 5759546 (1998-06-01), Weinberg et al.
patent: 5977081 (1999-11-01), Marciani
patent: 6080725 (2000-06-01), Marciani
patent: 6093382 (2000-07-01), Wedeking et al.
patent: 6204371 (2001-03-01), Levinson
patent: 6231859 (2001-05-01), Kensil
patent: 6262029 (2001-07-01), Press et al.
patent: 6270766 (2001-08-01), Feldman et al.
patent: 6335434 (2002-01-01), Guzaev et al.
patent: 7033594 (2006-04-01), Low et al.
patent: 7223380 (2007-05-01), Yang et al.
patent: 7601332 (2009-10-01), Vlahov et al.
patent: 2001/0031252 (2001-10-01), Low et al.
patent: 2002/0192157 (2002-12-01), Low et al.
patent: 2003/0086900 (2003-05-01), Low et al.
patent: 2003/0162234 (2003-08-01), Jallad et al.
patent: 2003/0198643 (2003-10-01), Lu
patent: 2004/0136910 (2004-07-01), Jallad et al.
patent: 2005/0002942 (2005-01-01), Vlahov et al.
patent: 2005/0164906 (2005-07-01), Riccardi
patent: 2005/0244336 (2005-11-01), Low
patent: 2005/0261170 (2005-11-01), Hansen et al.
patent: 2006/0002891 (2006-01-01), Pouletty
patent: 2006/0067946 (2006-03-01), Low et al.
patent: 2006/0204565 (2006-09-01), Low et al.
patent: 2007/0009434 (2007-01-01), Low et al.
patent: 2007/0231266 (2007-10-01), Low et al.
patent: 2007/0276231 (2007-11-01), Low et al.
patent: 2008/0119475 (2008-05-01), Low et al.
patent: 2008/0138396 (2008-06-01), Low et al.
patent: 2008/0254499 (2008-10-01), Low et al.
patent: 2009/0012009 (2009-01-01), Low et al.
patent: 2009/0214636 (2009-08-01), Low et al.
patent: 1548027 (2005-06-01), None
patent: WO 96/12096 (1990-10-01), None
patent: WO 94/07542 (1994-04-01), None
patent: WO 96/36367 (1996-11-01), None
patent: 97/37690 (1997-10-01), None
patent: WO 98/58678 (1998-12-01), None
patent: WO 99/41285 (1999-08-01), None
patent: 2001/19320 (2001-03-01), None
patent: WO 01/39806 (2001-06-01), None
patent: WO 01/74382 (2001-10-01), None
patent: WO 02/087424 (2002-11-01), None
patent: WO 03/092742 (2003-11-01), None
patent: WO 2004/100983 (2004-11-01), None
patent: WO 2004/110250 (2004-12-01), None
patent: WO 2005/069994 (2005-08-01), None
patent: WO 2006/012527 (2006-02-01), None
patent: WO 2006/101845 (2006-09-01), None
patent: WO 2008/148001 (2008-12-01), None
Feldman et al Transplant. Proc. 1998, 30, 4126-4127.
Cochlovius et al ., Modern Drug Discovery, 2003, pp. 33-38.
Mestas et al J. of Immunology, 2004, 172, pp. 2731-2738.
Van Noort et al. International Review of Cytology, 1998, v.178, pp. 127-204.
Sudimack et al. Advanced Drug Delivery Reviews, 2000, vol. 41, pp. 147-162.
Holmgren et al., Am J. Trop Med Hyd, 1994, 50, pp. 42-54.
“Folate-Targeted Enzyme Prodrug Cancer Therapy Utilizing Penicillin-V Amidase and A Doxorubicin Prodrug,” Lu, et al.J. Drug Targeting7: 43-53 (1999).
“Selective Targeting of Malignant Cells with Cytotoxin-Folate Conjugates,” Leamon, et al.J. Drug Targeting2:101-112 (1994).
“Targeted Drug Delivery via the Folate Receptor,” Sudimack et al.Adv. Drug Delivery Reviews41: 147-162 (2000).
“Folate-Mediated Targeting of Therapeutic and Imaging Agents to Cancers,” Reddy et al.Critical Reviews in Ther. Drug Carrier Systems15: 587-627 (1998).
“Optimization of Folate-Conjugated Liposomal Vectors for Folate Receptor-Mediated Gene Therapy,” Reddy et al.J. Pharm. Sciences88: 1112-1118 (1999).
Turk, Mary Jo et al.; “Folate-targeted imaging of activated macrophages in rats with adjuvant-induced arthritis,” Arthritis and Rheumatism, United States, Jul. 2002, vol. 46, No. 7, pp. 1947-1955, XP002284074.
Leamon, Christopher P. et al.; “Synthesis and biological evaluation of EC20: A new folate-derived, 99mTc-based radiopharmaceutical”, Bioconjugate Chemistry, vol. 13, No. 6, pp. 1200-1210, XP002284075.
Nakashima et al., Selective Expression of Folate Receptor Beta and its Possible Role in Methotrexate Transport in Synovial Macrophages from Patients with Rheumatoid Arthritis, Arthritis Rheum. 42(8): 1609-1616 (1999).
G. Robbin Westerhof, Jan C. Schornagel, Ietje Kathmann, Ann L. Jackman, Andre Rosowsky, Ronald A. Forsch, John B. Hynes, F. Thomas Boyle, Godefridus J. Peters, Herbert M. Pinedo, and Gerrit Jansen; “Carrier-and Receptor-Mediated Transport of Folate Antagonists Targeting Folate-Dependent Enzymes: Correlates of Molecular-Structure and Biological Activity,” journal article, Molecular Pharmacology, 1995, Vol. No. 48, pp. 459-471.
Eugene C. Roberts and Y. Fulmer Shealy; “Folic Acid Analogs. Modifications in the Benzene-Ring Region. 3. Neohomofolic and Neobishomofolic Acids. An Improved Synthesis of Folic Acid and Its Analogs.”, journal article, Journal of Medicinal Chemistry, 1973, vol. 16, No. 6, pp. 697-699.
Eugene C. Roberts and Y. Fulmer Shealy, “Folic Acid Analogs. Modifications in the Benzene-Ring Region. 2. Thiazole Analogs,” journal article, Journal of Medicinal Chemistry, 1972, vol. 15, No. 12, pp. 1310-1312.
Eugene C. Roberts and Y. Fulmer Shealy, “Folic Acid Analogs. Modifications in the Benzene-Ring Region. 1. 2′- and 3′- Azafolic Acids,” journal article, Journal of Medicinal Chemistry, 1971, vol. 14, No. 2, pp. 125-130.
Louis T. Weinstock, Bernard F. Grabowski, and C. C. Cheng, “Folic Acid Analogs. II. p-{[2,6-Diamino-8-purinyl)methyl]amino}—benzoyl-L-glutamic Acid and Related Compounds,” journal article, Journal of Medicinal Chemistry, 1970, vol. 13, No. 5, pp. 995-997.
Lothar Bock, George H. Miller, Klaus-J. Schaper, and Joachim K. Seydel, “Sulfonamide Structure-Activity Relationships in a Cell-Free System. 2. Proof for the Formation of a Sulfonamide-Containing Folate Analog.,” journal article, Journal of Medicinal Chemistry, 1974, vol. 17, No. 1, pp. 23-28.
Eugene C. Roberts and Y. Fulmer Shealy, “Folic Acid Analogs. Modifications in the Benzene-Ring Region. 4. 3′- Ethyl—and 3′- Isopropylfolic Acids,” journal article, Journal of Medicinal Chemistry, 1974, vol. 17, No. 2, pp. 219-222.
William W. Lee, Abelardo P. Martinez, and Leon Goodman, &

Affiliated with

Also associated with

Rating

Treatment of macrophage mediated disease does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of macrophage mediated disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of macrophage mediated disease will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4240354